David A. Siegel Bridge Bio Pharma, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 40,855 shares of BBIO stock, worth $1.17 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
40,855
Previous 252,820
83.84%
Holding current value
$1.17 Million
Previous $6.4 Million
83.76%
% of portfolio
0.0%
Previous 0.01%
Shares
16 transactions
Others Institutions Holding BBIO
# of Institutions
290Shares Held
170MCall Options Held
10.4MPut Options Held
2.37M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY25.3MShares$721 Million35.94% of portfolio
-
Viking Global Investors LP25.1MShares$717 Million2.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.2MShares$405 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$355 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$173 Million63.58% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $4.23B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...